Open Access Open Access  Restricted Access Subscription or Fee Access

Effectiveness of opioid rotation in the control of cancer pain: The ROTODOL Study

Jesús González-Barboteo, MD, Xavier Gómez-Batiste Alentorn, MD, PhD, Felipe A. Calvo Manuel, MD, PhD, Vicente Alberola Candel, MD, M. Amalia Palacios Eito, MD, Isabel Sánchez-Magro, MD, PhD, F. Javier Pérez Martín, PhD, Josep Porta-Sales, MD, PhD

Abstract


Objective: To assess the effectiveness of opioid rotation (OR) to manage cancer pain. To describe the adverse events (AEs) associated with OR.

Setting: Thirty-nine tertiary hospital services.

Patients: Sixty-seven oncological patients with cancer-related pain treated at outpatient clinics.

Intervention: Prospective multicenter study. Pain intensity was scored using a Numerical Rating Scale (NRS) of 0-10. Average pain (AP) intensity in the last 24 hours, breakthrough pain (BTP), and the number of episodes of BTP on the days before and 1 week after OR were assessed. The pre-OR and post-OR opioid were recorded. The presence and intensity of any AEs occurring after OR were also recorded.

Results: In the 67 patients evaluated, 75 ORs were recorded. In all cases, the main reason for OR was poor pain control. Pain intensity decreased by 2 points after OR in 75.4 percent and 57.8 percent of cases for AP and BTP, respectively. If the initial NRS score was 4, a decrease below <4 accounted for 50.9 percent and 32.3 percent of cases for AP and BTP, respectively. The number of episodes of BTP also decreased significantly (p < 0.001). A total of 107 AEs were reported, most of which were mild in intensity, with gastrointestinal symptoms predominating.

Conclusions: Opioid rotation appears to be both safe and effective in the management of basal and breakthrough cancer pain.


Keywords


analgesics, opioid/administration and dosage, pain, neoplasms

Full Text:

PDF

References


World Health Organization: WHO Cancer Pain Relief, with a Guide to Opioid Availability. Geneva: World Health Organization, 1996.

Zech DF, Grond S, Lynch J, et al.: Validation of World Health Organization Guidelines for cancer pain relief: A 10-year prospective study. Pain. 1995; 63(1): 65-76.

Porta-Sales J, Gómez-Batiste X, Tuca-Rodriguez A, et al.: WHO analgesic ladder—Or lift? Eur J Palliat Care. 2003; 10: 105-109.

Hanks GW, Conno F, Cherny N, et al.: Morphine and alternative opioids in cancer pain: The EAPC recommendations. Br J Cancer. 2001; 84(5): 587-593.

Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain. Part 1: Clinical considerations. J Pain Symptom Manage. 2001; 21(2): 144-150.

González-Barboteo J, Trelis-Navarro J, Tuca-Rodríguez A, et al.: Opioid rotation: A therapeutic choice in the management of refractory cancer pain. Med Clin (Barc). 2010; 135(13): 617-622.

Quigley C: Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev. 2004; 3(3): CD004847.

Mercadante S, Bruera E: Opioid switching: A systematic and critical review. Cancer Treat Rev. 2006; 32(4): 304-315.

Vadalouca A, Moka E, Argyra E, et al.: Opioid rotation in patients with cancer: A review of the current literature. J Opioid Manag. 2008; 4(4): 213-250.

Mercadante S: Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer. 1999; 86(9): 1856-1866.

Ross JR, Riley J, Quigley C, et al.: Clinical pharmacology and pharmacotherapy of opioid switching in cancer patients. Oncologist. 2006; 11(7): 765-773.

Pasternak GW: Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci. 2001; 22(2): 67-70.

Bolan EA, Tallarida RJ, Pasternak GW: Synergy between mu opioid ligands: Evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther. 2002; 303(2): 557-562.

Dong Z, Cao J, Xu L: Opiate withdrawal modifies synaptic plasticity in subicular-nucleus accumbens pathway in vivo. Neuroscience. 2007; 144(3): 845-854.

Pu L, Bao G-B, Xu N-J, et al.: Hippocampal long-term potentiation is reduced by chronic opiate treatment and can be restored by re-exposure to opiates. J Neurosci. 2002; 22(5): 1914-1921.

Ho S-T, Wang J-J, Huang J-C, et al.: The magnitude of acute tolerance to morphine analgesia: Concentration-dependent or time-dependent? Anesth Analg. 2002; 95(4): 948-951.

Fischer BD, Carrigan KA, Dykstra LA: Effects of N-methyld-aspartate receptor antagonists on acute morphine-induced and l-methadone-induced antinociception in mice. J Pain. 2005; 6(7): 425-433.

Baker AK, Hoffmann VLH, Meert TF: Dextromethorphan and ketamine potentiate the antinociceptive effects of mu- but not delta- or kappa-opioid agonists in a mouse model of acute pain. Pharmacol Biochem Behav. 2002; 74(1): 73-86.

Duttaroy A, Yoburn BC: The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 1995; 82(5): 1226-1236.

Riley J, Ross JR, Rutter D, et al.: No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2006; 14(1): 56-64.

Vigano A, Fan D, Bruera E: Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain. 1996; 67(1): 115-119.

Cherny NJ, Chang V, Frager G, et al.: Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995; 76(7): 1283-1293.

De Stoutz ND, Bruera E, Suarez-Almazor M: Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage. 1995; 10(5): 378-384.

Ashby MA, Martin P, Jackson KA: Opioid substitution to reduce adverse effects in cancer pain management. Med J Aust. 1999; 170(2): 68-71.

Bruera E, Pereira J, Watanabe S, et al.: Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996; 78(4): 852-857.

Gagnon B, Bruera E: Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage. 1999; 18(2): 120-125.

Mercadante S, Ferrera P, Villari P, et al.: Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage. 2009; 37(4): 632-641.

Bruera E, MacMillan K, Hanson J, et al.: The Edmonton Staging System for cancer pain: Preliminary report. Pain. 1989; 37(2): 203-209.

Porta-Sales J, Rodriguez-Mesa D, Sala-Rovira C: Dolor. In Porta-Sales J, Gómez-Batiste X, Tuca-Rodríguez A (eds.): Manual de control de síntomas en pacientes con cáncer avanzado y terminal. 2nd ed. Madrid: Arán Ediciones S.L., 2008: 45-111.

U.S. Department of Health and Human Services. National Institutes of Health National: Common Terminology Criteria for Adverse Events (CTCAE) version v4.03. 2010. Available at http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf. Accessed November 11, 2014.

Porta-Sales J, Codorniu N, Gómez-Batiste X, et al.: Patient appointment process, symptom control and prediction of follow-up compliance in a palliative care outpatient clinic. J Pain Symptom Manage. 2005; 30(2): 145-153.

Daut RL, Cleeland CS: The prevalence and severity of pain in cancer. Cancer. 1982; 50(9): 1913-1918.

Serlin RC, Mendoza TR, Nakamura Y, et al.: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995; 61(2): 277-284.

Müller-Busch HC, Lindena G, Tietze K, et al.: Opioid switch in palliative care, opioid choice by clinical need and opioid availability. Eur J Pain. 2005; 9(5): 571-579.

Mercadante S, Casuccio A, Tirelli W, et al.: Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer. 2009; 17(6): 715-718.

Gatti A, Reale C, Luzi M, et al.: Effects of opioid rotation in chronic pain patients: ORTIBARN study. Clin Drug Investig. 2010; 30(Suppl 2): 39-47.

Farrar JT: What is clinically meaningful: Outcome measures in pain clinical trials. Clin J Pain. 2000; 16(2 Suppl): S106-S112.

Farrar JT, Portenoy RK, Berlin JA, et al.: Defining the clinically important difference in pain outcome measures. Pain. 2000; 88(3): 287-294.

Kloke M, Rapp M, Bosse B, et al.: Toxicity and/or insufficient analgesia by opioid therapy: Risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer. 2000; 8(6): 479-486.

Mercadante S, Portenoy RK: Opioid poorly-responsive cancer pain. Part 2: Basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage. 2001; 21(3): 255-264.

Collin E, Poulain P, Gauvain-Piquard A, et al.: Is disease progression the major factor in morphine “tolerance” in cancer pain treatment? Pain. 1993; 55(3): 319-326.

Fainsinger RL, Nekolaichuk CL, Lawlor PG, et al.: A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain Symptom Manage. 2005; 29(3): 224-237.

Mercadante S, Ferrera P, Villari P, et al.: Hyperalgesia: An emerging iatrogenic syndrome. J Pain Symptom Manage. 2003; 26(2): 769-775.

Mercadante S, Arcuri E: Hyperalgesia and opioid switching. Am J Hosp Palliat Care. 2005; 22(4): 291-294.




DOI: https://doi.org/10.5055/jom.2014.0236

Refbacks

  • There are currently no refbacks.